Reboxetine Enhances the Olanzapine-Induced Antipsychotic-Like Effect, Cortical Dopamine Outflow and NMDA Receptor-Mediated Transmission

The Rat Brain in Stereotaxic Coordinates

1982 • 53,055 citations

The rat brain in stereotaxic coordinates

1983 • 28,962 citations

Clozapine for the Treatment-Resistant Schizophrenic

1988 • 4,030 citations

Comparative electrophysiology of pyramidal and sparsely spiny stellate neurons of the neocortex

1985 • 1,984 citations

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

2008 • 1,842 citations

Intrinsic firing patterns of diverse neocortical neurons

1990 • 1,447 citations

Clozapine Treatment for Suicidality in Schizophrenia<subtitle>International Suicide Prevention Trial (InterSePT)</subtitle>

2003 • 1,290 citations

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1996 • 1,143 citations

Relationship Between Dopamine D₂ Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia

2000 • 1,036 citations

A Meta-analysis of the Efficacy of Second-Generation Antipsychotics

2003 • 1,008 citations

Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment

2006 • 806 citations

Prefrontal Dopamine D₁Receptors and Working Memory in Schizophrenia

2002 • 724 citations

Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment

2006 • 719 citations

Central D2-Dopamine Receptor Occupancy in Schizophrenic Patients Treated With Antipsychotic Drugs

1988 • 692 citations

Neurochemical Modulation of Response Inhibition and Probabilistic Learning in Humans

2006 • 560 citations

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction

2004 • 547 citations

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

2008 • 485 citations

Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia

2003 • 435 citations

Acute Effects of Typical and Atypical Antipsychotic Drugs on the Release of Dopamine from Prefrontal Cortex, Nucleus Accumbens, and Striatum of the Rat: An In Vivo Microdialysis Study

1990 • 407 citations

Blockade of the Noradrenaline Carrier Increases Extracellular Dopamine Concentrations in the Prefrontal Cortex: Evidence that Dopamine Is Taken up In Vivo by Noradrenergic Terminals

1990 • 407 citations

Randomized Controlled Trial of Effect of Prescription of Clozapine Versus Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia

2005 • 406 citations

Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review

2007 • 345 citations

D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients

1995 • 341 citations

The Increasing Use of Polypharmacotherapy for Refractory Mood Disorders

2000 • 319 citations

Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability

2005 • 318 citations

Introduction to Experimental Statistics.

1965 • 278 citations

Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia

2003 • 276 citations

Suicidal risk during treatment with clozapine: a meta-analysis

2004 • 266 citations

Clinical Pharmacokinetics of Reboxetine, a Selective Norepinephrine Reuptake Inhibitor for the Treatment of Patients with Depression

2000 • 252 citations

Dopamine D2 Receptor Occupancy Is a Common Mechanism Underlying Animal Models of Antipsychotics and Their Clinical Effects

2001 • 251 citations

Lamina-Specific Abnormalities of NMDA Receptor-Associated Postsynaptic Protein Transcripts in the Prefrontal Cortex in Schizophrenia and Bipolar Disorder

2007 • 246 citations

Pharmacological Specificity of Conditioned Avoidance Response Inhibition in Rats: Inhibition by Neuroleptics and Correlation to Dopamine Receptor Blockade

1982 • 238 citations

In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems

2008 • 237 citations

Extended-Release Quetiapine as Adjunct to an Antidepressant in Patients With Major Depressive Disorder

2009 • 201 citations

Modulators in concert for cognition: Modulator interactions in the prefrontal cortex

2007 • 199 citations

Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex

2001 • 191 citations

Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum

1998 • 190 citations

The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?

1999 • 186 citations

Enhanced Cortical Dopamine Output and Antipsychotic-like Effects of Raclopride by α ₂ Adrenoceptor Blockade

1999 • 171 citations

Dopamine D 2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats

2000 • 159 citations

Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro.

1997 • 158 citations

Introduction to Experimental Statistics.

1965 • 154 citations

Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study

2009 • 140 citations

Extended Release Quetiapine Fumarate Monotherapy in Major Depressive Disorder

2009 • 135 citations

α-Adrenoceptor modulation hypothesis of antipsychotic atypicality

2003 • 132 citations

Attenuation of Olanzapine-Induced Weight Gain With Reboxetine in Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Study

2003 • 131 citations

On the Origin of Cortical Dopamine: Is it a Co-Transmitter in Noradrenergic Neurons?

2006 • 128 citations

Special Section on Implications of CATIE: What CATIE Found: Results From the Schizophrenia Trial

2008 • 127 citations

Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex

1994 • 126 citations

Occupancy of Striatal and Extrastriatal Dopamine D2 Receptors by Clozapine and Quetiapine

2006 • 123 citations

New indications for antidepressants.

2000 • 121 citations

Idazoxan, an α-2 antagonist, facilitates memory retrieval in the rat

1989 • 120 citations

Evidence that Extracellular Concentrations of Dopamine Are Regulated by Noradrenergic Neurons in the Frontal Cortex of Rats

1994 • 115 citations

Interaction of Dopamine D1 and NMDA Receptors Mediates Acute Clozapine Potentiation of Glutamate EPSPs in Rat Prefrontal Cortex

2002 • 109 citations

Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients

2003 • 104 citations

Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: A comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission

1986 • 102 citations

In vivo 123 I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol

1999 • 87 citations

Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain

1998 • 83 citations

Combined α2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat

2005 • 80 citations

Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood

2006 • 79 citations

Refractory schizophrenia and atypical antipsychotics

2000 • 78 citations

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study

2007 • 74 citations

Reboxetine: additional benefits to the depressed patient.

1997 • 71 citations

Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia

2007 • 64 citations

A Pilot Study of Adjunctive Atomoxetine Treatment to Second-Generation Antipsychotics for Cognitive Impairment in Schizophrenia

2008 • 60 citations

Differential effects of atypical and typical antipsychotic drugs on N‐methyl‐D‐aspartate‐ and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex

2003 • 56 citations

Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive α2 adrenoceptor blockade: experimental evidence

2006 • 56 citations

Change-over designs.

2004 • 55 citations

Adjunctive α2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission

2009 • 51 citations

Noradrenaline Reuptake Inhibition Enhances the Antipsychotic-like Effect of Raclopride and Potentiates D2-blockage–induced Dopamine Release in the Medial Prefrontal Cortex of the Rat

2002 • 47 citations

The Treatment of Negative Symptoms: Pharmacological and Methodological Issues

1996 • 44 citations

From symptoms to social functioning: differential effects of antidepressant therapy

1999 • 42 citations

Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study

2001 • 40 citations

Inhibition of the glycine transporter GlyT‐1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex

2006 • 33 citations

BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia

2008 • 33 citations

Adjunctive use of reboxetine in schizophrenia

2004 • 32 citations

Modulation of the ability of clozapine to facilitate NMDA‐ and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: pharmacological evidence

2003 • 32 citations

A new computer-assisted two-way avoidance conditioning equipment for rats: Behavioral and pharmacological validation

1994 • 31 citations

Treatment Response to Olanzapine and Haloperidol and its Association with Dopamine D₂ Receptor Occupancy in First-Episode Psychosis

2005 • 29 citations

Bioanalysis of Racemic Reboxetine and Its Desethylated Metabolite in a Therapeutic Drug Monitoring Setting Using Solid Phase Extraction and HPLC

2001 • 28 citations

A meta-analysis of the response to chronic l-dopa in patients with schizophrenia: therapeutic and heuristic implications

2004 • 27 citations

Enhanced Cortical Dopamine Output and Antipsychotic-like Effect of Raclopride with Adjunctive Low-Dose L-dopa

2005 • 21 citations

Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.

2009 • 20 citations

Preclinical effects of conventional and atypical antipsychotic drugs: defining the mechanisms of action

2003 • 20 citations

P.1.c.022 PET-measured D2, 5-HT2, and norepinephrine transporter (NET) occupancy by quetiapine and N-desalkyl-quetiapine in non-human primates

2007 • 11 citations